Mitchell S Cairo

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report
    M S Cairo
    Babies and Children s Hospital, Columbia University, New York, New York, USA
    J Pediatr Hematol Oncol 23:30-8. 2001
  2. ncbi request reprint Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report
    Mitchell S Cairo
    Georgetown University, Washington, DC, USA
    Transfusion 45:856-66. 2005
  3. ncbi request reprint Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Pediatr Blood Cancer 45:753-69. 2005
  4. ncbi request reprint Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, NY, USA
    Br J Haematol 128:49-58. 2005
  5. ncbi request reprint Tumour lysis syndrome: new therapeutic strategies and classification
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Br J Haematol 127:3-11. 2004
  6. doi request reprint Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors
    Mitchell S Cairo
    Morgan Stanley Children s Hospital, New York Presbyterian, Columbia University, New York, New York, USA
    Biol Blood Marrow Transplant 14:44-53. 2008
  7. pmc NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem c
    Mitchell S Cairo
    Department of Pediatrics, Medicine, and Pathology, Columbia University, Morgan Stanley Children s Hospital, New York Presbyterian Hospital, New York, New York 10032, USA
    Biol Blood Marrow Transplant 16:709-28. 2010
  8. pmc Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
    Mitchell S Cairo
    Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Blood 109:2736-43. 2007
  9. ncbi request reprint Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital New York, Columbia University, New York, NY, USA
    Br J Haematol 120:660-70. 2003
  10. ncbi request reprint Prevention and treatment of hyperuricemia in hematological malignancies
    Mitchell S Cairo
    Department of Pediatrics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Clin Lymphoma 3:S26-31. 2002

Research Grants

Detail Information

Publications66

  1. ncbi request reprint Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report
    M S Cairo
    Babies and Children s Hospital, Columbia University, New York, New York, USA
    J Pediatr Hematol Oncol 23:30-8. 2001
    ..10.0 microg/kg per day) after ifosfamide, carboplatin, and etoposide (ICE) chemotherapy; and 2) to determine the response rate (complete response [CR] + partial response [PR]) of ICE in children with refractory or recurrent solid tumors...
  2. ncbi request reprint Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report
    Mitchell S Cairo
    Georgetown University, Washington, DC, USA
    Transfusion 45:856-66. 2005
    ..The study goals were to develop standard operating procedures for cord blood (CB) donor recruitment and banking and to build an ethnically diverse unrelated CB bank to support a transplantation protocol...
  3. ncbi request reprint Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Pediatr Blood Cancer 45:753-69. 2005
    ....
  4. ncbi request reprint Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, NY, USA
    Br J Haematol 128:49-58. 2005
    ....
  5. ncbi request reprint Tumour lysis syndrome: new therapeutic strategies and classification
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Br J Haematol 127:3-11. 2004
    ..We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme...
  6. doi request reprint Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors
    Mitchell S Cairo
    Morgan Stanley Children s Hospital, New York Presbyterian, Columbia University, New York, New York, USA
    Biol Blood Marrow Transplant 14:44-53. 2008
    ..In this article we review the experience of both unrelated cord blood donor and haploidentical family donor transplants in selected pediatric malignant and nonmalignant conditions...
  7. pmc NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem c
    Mitchell S Cairo
    Department of Pediatrics, Medicine, and Pathology, Columbia University, Morgan Stanley Children s Hospital, New York Presbyterian Hospital, New York, New York 10032, USA
    Biol Blood Marrow Transplant 16:709-28. 2010
    ....
  8. pmc Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
    Mitchell S Cairo
    Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Blood 109:2736-43. 2007
    ..001). Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (B-ALL with or without CNS involvement)...
  9. ncbi request reprint Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital New York, Columbia University, New York, NY, USA
    Br J Haematol 120:660-70. 2003
    ..001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy...
  10. ncbi request reprint Prevention and treatment of hyperuricemia in hematological malignancies
    Mitchell S Cairo
    Department of Pediatrics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Clin Lymphoma 3:S26-31. 2002
    ..In summary, in the prevention and treatment of hyperuricemia, patients with hematological malignancies at risk of tumor lysis syndrome appear to benefit significantly from the use of a recombinant urate oxidase (rasburicase)...
  11. doi request reprint Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, Morgan Stanley Children s Hospital, NY Presbyterian, New York, NY, USA
    Br J Haematol 149:578-86. 2010
    ....
  12. ncbi request reprint Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, New York, USA
    Am J Hematol 72:53-63. 2003
    ..Large numbers of patients treated with shorter and intense therapy are required to confirm these preliminary observations...
  13. pmc A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients
    Mark B Geyer
    Department of Pediatrics, NewYork Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY, USA
    Br J Haematol 155:218-34. 2011
    ..The use of adoptive cellular immunotherapy to accelerate immune reconstitution and prevent and treat opportunistic infections and malignant relapse following UCBT warrants further investigation...
  14. doi request reprint A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regim
    Prakash Satwani
    Department of Pediatric, New York Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY, USA
    Biol Blood Marrow Transplant 18:324-9. 2012
    ..8-73.6). GO combined with Bu/Cy regimen followed by alloSCT is well tolerated in children with poor-risk AML. GO at 7.5 mg/m(2) in combination with Bu/Cy is currently being tested in a phase II study...
  15. doi request reprint Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients
    Prakash Satwani
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Biol Blood Marrow Transplant 19:552-61. 2013
    ..03). Reduced-toxicity conditioning allo-HSCT in pediatric recipients is associated with low TRM; however, chemotherapy-naive UCBT recipients have a significantly higher incidence of PGF...
  16. doi request reprint An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients
    Monica Bhatia
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Biol Blood Marrow Transplant 16:333-43. 2010
    ..Children <12 years of age appear to have a significantly different MPA PK profile compared to older children and adolescents and may require more frequent dosing...
  17. doi request reprint Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy
    Janet Ayello
    Department of Pediatrics, Morgan Stanley Children s Hospital of New York Presbyterian Hospital and Columbia University, New York, NY 10032, USA
    Exp Hematol 37:1216-29. 2009
    ....
  18. ncbi request reprint A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Gro
    Anne L Angiolillo
    Children s National Medical Center, George Washington University, Washington, DC, USA
    Clin Cancer Res 11:2644-50. 2005
    ..2, 2.4, or 3.6 microg/kg per dose...
  19. doi request reprint Differential gene expression signatures of adult peripheral blood vs cord blood monocyte-derived immature and mature dendritic cells
    Hong Jiang
    Department of Pediatrics, Morgan Stanley Children s Hospital New York Presbyterian, Columbia University, New York, NY 10032, USA
    Exp Hematol 37:1201-15. 2009
    ..Our previous studies have demonstrated differentially expressed genetic signature patterns in adult peripheral blood (APB) monocytes (Mos) vs cord blood (CB) Mos...
  20. doi request reprint Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant
    Prakash Satwani
    Department of Pediatrics, New York Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY, USA
    Biol Blood Marrow Transplant 17:1472-80. 2011
    ..31, P = .013), no KI versus KI (HR 2.00, P = .005). In children, MAC is associated with significant risk of KI in the first month after transplant, and KI in the first month post-AlloSCT is associated with a significantly decreased OS...
  21. doi request reprint Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients
    Prakash Satwani
    Department of Pediatrics, Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, New York 10032, USA
    Biol Blood Marrow Transplant 15:1587-95. 2009
    ..4-210.8; P=< .01). Overall infection-related mortality was only 1.1% (1/86) for SVIs and 2.3% (2/86) for IFIs. Our data indicate that RIC allo-SCT does not carry a lower risk of SVIs and IFIs than MAC allo-SCT in pediatric recipients...
  22. ncbi request reprint Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia
    Elizabeth Roman
    Department of Pediatrics, Columbia University, New York, New York 10032, USA
    Clin Cancer Res 11:7164s-7170s. 2005
    ..There are no safety data with gemtuzumab ozogamicin post allogeneic SCT in children. Therefore, we explored the feasibility and toxicity of targeted immunotherapy following reduced-intensity allogeneic SCT in children with CD33+ AML...
  23. ncbi request reprint Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation
    Elizabeth Roman
    Department of Pediatrics, Columbia University, New York, New York, USA
    Pediatr Blood Cancer 50:325-30. 2008
    ..We initiated a pilot study to determine the safety and activity of prophylactic liposomal amphotericin B (AMB) in preventing IMI in pediatric and adolescent AlloSCT recipients during the first 100 days...
  24. ncbi request reprint A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients
    Elif Unal
    Department of Pediatrics, Columbia University, New York, New York 10032, USA
    Biol Blood Marrow Transplant 12:1188-97. 2006
    ..Multicenter studies are needed to identify the risk factors, early diagnostic criteria, and optimal therapy...
  25. pmc Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report
    Matthew J Barth
    Division of Pediatric Hematology Oncology, University at Buffalo, Buffalo, NY, USA
    Br J Haematol 162:678-83. 2013
    ..Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½...
  26. ncbi request reprint Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases
    Prakash Satwani
    Department of Pediatrics, Columbia University, New York, New York, USA
    Pediatr Blood Cancer 50:1-8. 2008
    ....
  27. ncbi request reprint Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering
    Janet Ayello
    Department of Pediatrics, Columbia University, New York, New York 10032, USA
    Biol Blood Marrow Transplant 12:608-22. 2006
    ..005, respectively). These data suggest that cryopreserved CB cells could be ex vivo engineered for potential use as adoptive cancer cellular immunotherapy for donor lymphocyte infusion after CBT...
  28. doi request reprint Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality
    Diane George
    Department of Pediatrics, NewYork Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY 10032, USA
    Br J Haematol 156:99-108. 2012
    ....
  29. pmc Unrelated umbilical cord blood transplantation and immune reconstitution
    Paul Szabolcs
    Department of Pediatrics, Division of Pediatric Bone Marrow Transplantation, Duke University Medical Center, Durham, NC, USA
    Semin Hematol 47:22-36. 2010
    ..Novel cellular therapies that are about to enter the clinical setting in the form of natural killer (NK) cell and T-cell therapies in the form of donor lymphocyte infusion (DLI) are also discussed...
  30. ncbi request reprint Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges
    Prakash Satwani
    Department of Pediatrics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
    Biol Blood Marrow Transplant 11:403-22. 2005
    ..We review the recent experience of RI AlloSCT in adults and children with both malignant and nonmalignant diseases and discuss the challenges for the future...
  31. ncbi request reprint A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients
    Evan B Shereck
    Department of Pediatrics, Columbia University, and Division of Pediatric Hematology and Blood and Marrow Transplantation, Morgan Stanley Children s Hospital of New York Presbyterian, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA
    Pediatr Blood Cancer 49:306-12. 2007
    ..We hypothesized that alternate day ganciclovir and foscarnet for the prevention of CMV during the first 100 days after AlloSCT would be safe and effective...
  32. doi request reprint Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning
    Ian M Waxman
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Pediatr Transplant 13:464-74. 2009
    ..In summary, it was demonstrated that sequential administration of GM-CSF/G-CSF post-MA-alloSCT was safe, cost-effective and resulted in prompt myeloid engraftment...
  33. ncbi request reprint Prophylactic use of myelopoietic growth factors in children after myelosuppressive and myeloablative therapy
    Prakash Satwani
    Department of Pediatrics, Children s Hospital New York Presbyterian, Columbia University, 161 Fort Washington, Irving 7, New York, NY 10032, USA
    Curr Hematol Rep 2:480-90. 2003
    ..Additional pediatric studies comparing the safety, efficacy, and cost effectiveness of granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor are needed...
  34. ncbi request reprint Dysregulation of expression of immunoregulatory and cytokine genes and its association with the immaturity in neonatal phagocytic and cellular immunity
    Prakash Satwani
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Biol Neonate 88:214-27. 2005
    ..However, immaturity of innate and adaptive immune responses in the perinatal period predisposes the neonate to increased infectious morbidity and mortality from a variety of organisms...
  35. pmc Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents
    Thomas G Gross
    Department of Pediatrics, Nationwide Children s Hospital, Ohio State University, Columbus, Ohio 43205, USA
    Biol Blood Marrow Transplant 16:223-30. 2010
    ..These data were unable to demonstrate a difference in outcome by donor type for the other histological subtypes...
  36. doi request reprint Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function
    Prakash Satwani
    Department of Pediatrics, Columbia University, New York, New York 10032, USA
    Cytotherapy 13:730-8. 2011
    ..Previously, we have demonstrated significant ex vivo expansion and activation of unrelated cord blood (UCB) NK cells with an antibody/cytokine cocktail consisting of anti-CD3 + IL-2 + IL-12 + IL-7 and anti-CD3 + IL-2 + IL-12 + IL-18...
  37. ncbi request reprint Cord blood immunology and stem cell transplantation
    M Brigid Bradley
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Hum Immunol 66:431-46. 2005
    ....
  38. doi request reprint CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation
    Manuela A Orjuela
    Departments of Pediatrics, Columbia University, New York Presbyterian Morgan Stanley Children s Hospital New York, NY, USA
    Br J Haematol 152:733-42. 2011
    ..56·3%, P = 0·01). EBV expression was unrelated to PTLD-related EFS or OS. CD20 expression is associated with timing of development of PTLD and predicts survival in PTLD diagnosed following paediatric SOT...
  39. ncbi request reprint Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function
    Prakash Satwani
    Department of Pediatrics, Columbia University, New York, NY, USA
    Br J Haematol 130:284-92. 2005
    ..These results may have implications for the mechanism(s) in part responsible for the immaturity of CB T-cell immunity...
  40. ncbi request reprint Myeloid hematopoietic growth factors and their role in prevention and/or treatment of neonatal sepsis
    Elvira Parravicini
    Divisions of Pediatric Oncology and Neonatology, Department of Pediatrics, Columbia University, New York, NY, USA
    Transfus Med Rev 16:11-24. 2002
    ....
  41. pmc Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report
    Prakash Satwani
    Morgan Stanley Children s Hospital of NewYork Presbyterian, Columbia University, New York, New York 10032, USA
    Biol Blood Marrow Transplant 13:218-27. 2007
    ..Randomized prospective cooperative group studies are required to establish the role of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in children with UHRF ALL in CR1...
  42. ncbi request reprint A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study
    Erin Cooney-Qualter
    Division of Pediatric Heamtology and Blood and Marrow Transplantation, Medicine and Pathology, Columbia University, New York, New York 10032, and Children s Hospital of Philadelphia, PA, USA
    Clin Cancer Res 13:5652s-5660s. 2007
    ..There is no data on the safety and feasibility of 90Y-IT in refractory childhood CD20+ lymphoma...
  43. ncbi request reprint B large-cell lymphoma in children and adolescents
    Elizabeth Raetz
    Mount Sinai School of Medicine, 1 Gustave Levy Place, 1208, New York, NY 10029, USA
    Cancer Treat Rev 29:91-8. 2003
    ....
  44. ncbi request reprint Immunotherapy in the prophylaxis and treatment of neonatal sepsis
    Mandhir Suri
    Children s Hospital of New York Presbyterian, Divisions of Pediatric Oncology and Neonatology, and Department of Pediatrics, Columbia University, New York, New York, USA
    Curr Opin Pediatr 15:155-60. 2003
    ....
  45. pmc Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008
    ....
  46. pmc Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells
    Munenari Itoh
    Departments of Dermatology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 108:8797-802. 2011
    ..Our studies indicate that autologous iPSCs have the potential to provide a source of cells for regenerative therapies for specific skin diseases...
  47. ncbi request reprint The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes
    Monica Bhatia
    Departments of Pediatrics, Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Leuk Lymphoma 48:9-15. 2007
    ....
  48. ncbi request reprint A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients
    Ifeyinwa Osunkwo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, New York, USA
    Biol Blood Marrow Transplant 10:246-58. 2004
    ..Further pharmacokinetic and pharmacodynamic studies are ongoing in pediatric and adolescent AlloSCT recipients to define optimal MMF dosing...
  49. ncbi request reprint Treatment of severe thrombocytopenia with IL-11 in children with Wiskott-Aldrich syndrome
    Kiery Braithwaite
    Department of Pediatrics and the Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Pediatr Hematol Oncol 24:323-6. 2002
    ..Larger studies are required to confirm this observation of the safety and efficacy of IL-11 in this setting...
  50. doi request reprint Cord blood transplantation and stem cell regenerative potential
    Yanling Liao
    Department of Pediatrics, New York Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY 10032, USA
    Exp Hematol 39:393-412. 2011
    ..In this review, we will summarize the most recent updates on clinical applications of cord blood transplantation and the promises and limitations of cell-based therapies for tissue repair and regeneration...
  51. ncbi request reprint Increased induction of allogeneic-specific cord blood CD4+CD25+ regulatory T (Treg) cells: a comparative study of naïve and antigenic-specific cord blood Treg cells
    Chih Chao Chang
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Exp Hematol 33:1508-20. 2005
    ..In this study, we investigated if cord blood (CB) CD4(+)CD25(+) T cells play a significant role in reducing the immune responses of allo-reactive CD4(+)CD25(-) T lymphocytes...
  52. ncbi request reprint Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome
    Olga Bessmertny
    Department of Pharmacy, Children s Hospital of New York Presbyterian, Columbia University, NY 10032, USA
    Curr Pharm Des 11:4177-85. 2005
    ....
  53. ncbi request reprint Human natural killer cells in health and disease
    Evan Shereck
    Department of Pediatrics, Columbia University, New York, New York, USA
    Pediatr Blood Cancer 49:615-23. 2007
    ..Further studies are required to determine optimal selection of donors and recipients, both on NKR matching/mismatching, undergoing haploidentical and unrelated hematopoetic stem cell transplantation...
  54. ncbi request reprint Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches
    Gustavo del Toro
    Division of Pediatric Hematology, Columbia University, 180 Fort Washington Avenue, New York, NY 10032, USA
    Clin Adv Hematol Oncol 3:54-61. 2005
    ..Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia...
  55. doi request reprint Central neurocytoma responsive to topotecan, ifosfamide, carboplatin
    Elham Amini
    Department of Pediatrics, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Pediatr Blood Cancer 51:137-40. 2008
    ..The complete response of central neurocytoma to chemotherapy only reported here should be helpful to those caring for patients with this rare tumor...
  56. ncbi request reprint Periostitis secondary to interleukin-11 (Oprelvekin, Neumega). Treatment for thrombocytopenia in pediatric patients
    Edward Milman
    Department of Radiology, Division of Pediatric Radiology, Children s Hospital of New York Presbyterian, 3959 Broadway, CHN 3 325, New York, NY 10032, USA
    Pediatr Radiol 33:450-2. 2003
    ..The pediatric doses (75 g/kg/d) are above those recommended for adult patients (50 g/kg/d) and this may account for the pediatric bone changes of periostitis...
  57. ncbi request reprint A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation
    Manuela Orjuela
    Departments of Pediatrics, Columbia University, New York, New York 10032, USA
    Clin Cancer Res 9:3945S-52S. 2003
    ..The response rate to immunotherapy (rituximab) is only about 46% with a 54% relapse/progression rate. In this study, we investigated the use of a combination of Cy/Pred with rituximab as treatment for this disease...
  58. ncbi request reprint Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay?
    Olga Bessmertny
    Department of Pharmacy, Children s Hospital of New York Presbyterian, Columbia University, New York 10032, USA
    J Pediatr Hematol Oncol 25:435-40. 2003
  59. doi request reprint Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission
    Jessica Hochberg
    Department of Pediatrics, New York Medical College, Valhalla, NY 10595, USA
    Br J Haematol 161:27-42. 2013
    ....
  60. doi request reprint Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science
    Jessica Hochberg
    Department of Pediatrics, Columbia University, New York, NY 10032, USA
    Br J Haematol 144:24-40. 2009
    ....
  61. ncbi request reprint Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation
    Kathleen L Robinson
    Department of Pediatrics, Georgetown University, Washington, DC, USA
    Exp Hematol 30:245-51. 2002
    ..We investigated whether umbilical cord blood (UCB) T cells could be ex vivo expanded and activated in short-term culture for potential utilization as adoptive cellular immunotherapy post-umbilical cord blood transplantation (UCBT)...
  62. ncbi request reprint Differential gene expression patterns by oligonucleotide microarray of basal versus lipopolysaccharide-activated monocytes from cord blood versus adult peripheral blood
    Hong Jiang
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    J Immunol 172:5870-9. 2004
    ..These results provide insight into the molecular basis for normal genetic regulation of Mo development and cellular function and differential inflammatory and innate and adaptive immune responses between activated CB and APB Mo...
  63. ncbi request reprint Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients
    Kenneth R Meehan
    Division of Hematology and Oncology, Bone Marrow Transplant Program, Georgetown University Medical Center and the Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
    J Hematother Stem Cell Res 11:415-21. 2002
    ..These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients...
  64. ncbi request reprint Rasburicase: future directions in tumor lysis management
    Jessica Hochberg
    Columbia University, Morgan Stanley Children s Hospital of NewYork Presbyterian, Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, 3959 Broadway, CHN 10 03, New York, NY 10032, USA
    Expert Opin Biol Ther 8:1595-604. 2008
    ..Rasburicase is a safe and effective hypouricemic agent for both adults and children at high risk for TLS and for this reason should be considered the uricolytic agent of choice in these patients...
  65. ncbi request reprint The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration
    Carmella van de Ven
    Department of Pediatrics, Columbia University and Morgan Stanley Children s Hospital New York Presbyterian, New York, NY 10032, USA
    Exp Hematol 35:1753-65. 2007
    ..This review will summarize the in vitro and in vivo studies examining UCB stem cells and their potential use for therapeutic application for nonhematopoietic tissue and cell regeneration...
  66. ncbi request reprint Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, New York, NY, USA
    Clin Lymphoma 3:233-4. 2003

Research Grants2

  1. Nonablative AlloSCT in Refractory Autoimmune Disease
    Mitchell Cairo; Fiscal Year: 2003
    ....
  2. First Int'l Symposium on Childhood and Adolescent NHL
    Mitchell Cairo; Fiscal Year: 2003
    ..abstract_text> ..